Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te
about
Current and emerging azole antifungal agentsMultidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care unitsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsAntifungal resistance in pathogenic fungiBlastoschizomyces capitatus infection in patients with leukemia: report of 26 casesUpregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitorsIn vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformansIn vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasisIn vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida sppIn vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolatesIn vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.Calcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2pSystematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genesFluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine CryptococcosisUsing a sequential regimen to eliminate bacteria at sublethal antibiotic dosagesEpidemiology of invasive candidiasis: a persistent public health problemComparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusionComparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazoleActivities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY ParBloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobiaCandida biofilms: an update.Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.Acrophialophora fusispora brain abscess in a child with acute lymphoblastic leukemia: review of cases and taxonomy.Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.Candida pseudorugosa sp. nov., a novel yeast species from sputum.Antifungal and immunomodulating activities of 1,4-benzothiazine azole derivatives: review.Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.Pharmacological advances in the treatment of invasive candidiasis.MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole.Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
P2860
Q24550733-21BDEED0-AC9A-4759-A259-8035162AE945Q24550785-50A8F8F1-A9DD-4801-9793-EB22991B902FQ27009221-8417A703-04B2-4941-89BF-025EB1D6D54EQ27025299-37310BEB-9E3E-494F-9988-0673E1BF8453Q28208165-344C6979-3CDD-4067-BC43-AEF171F746D1Q28239042-6A38854A-813A-44DC-8978-568BCA9EEB80Q28344744-15304EEF-EE6E-4C51-9617-2BFAF8CB959EQ28353303-AC39C6A0-997B-4282-BAE3-CDE0696DF9D8Q28369323-BA6DB864-6101-4C9D-9E63-E7AA72057272Q28379319-6BF7F7E7-2C5B-45F9-931C-DC440AD59474Q28379320-8B5455C8-73A6-437B-984D-CAAC74B1A7ABQ28379437-6AB58D31-19D1-47E2-B956-82933E7CFA79Q28379512-0F5EF8AA-1587-4A98-9F95-C4A4B8FAEA8CQ28484616-89B27728-9E4C-41CF-BD64-4D54BCE47435Q28539874-2A176467-840F-4AE2-95B8-87109BACFDE1Q28544939-6F8EA7C5-E0B7-413B-9F87-D8BE24916FA0Q28545933-1068FE7D-D2BF-4246-9643-4477EABFBC9EQ29616758-0D11F3BF-8EA1-4FD3-B2FA-55317A33067AQ30311996-C63B0300-F575-4C20-988C-CBD561BD66ADQ30449026-2C6AEAEE-1F66-4498-BEC7-60B8A68B5620Q30452376-74F6D332-026B-4F91-A0EE-A3984D343F14Q30452973-0034B94E-A5FE-4069-9641-D84AF5649A1DQ30452998-C6B3FE7F-79D5-4B8D-BE56-8A7C04BD0FB8Q30453032-FB9F7A42-D16A-4D36-8223-E3D46173F4EFQ30453440-AFB500B7-41F1-475C-B1BD-EF468E81281DQ30453663-80FC1ABE-0832-47AB-9920-A48FBAEB1D68Q30453666-5A366CEB-F581-4FAA-BAE3-241A7E991026Q30453797-F83C6383-FF93-488D-A96B-41135133BA7EQ30475833-E74823A2-AE07-4872-875F-FECD6FA5AD16Q30596962-FF153EA5-4E1F-477B-BD64-36E5BC8D2EC8Q30620420-E6E20C2A-E3EA-4D89-80C8-FD2FC98ED3CDQ30792309-4D6F463A-97C0-4DDE-900E-1974DEF9DD71Q31058690-340D3801-85BE-414E-A1DF-36938DA907A7Q31064491-12FBB2F2-6458-41CA-8442-17C705E13144Q32100806-2C68F02D-57D3-4B5B-87DA-CF691F08CFC5Q33183542-FB1A016B-D03B-49D7-8107-E0B5FBA28913Q33232599-391A0A5D-8365-430B-B089-AD600D70CCE7Q33502781-F71D0209-2A85-4C37-8B1C-F309DF73AD40Q33528384-D3A7EDDC-65A2-4303-8EA7-F96CB68FA22AQ33608832-0DCF0F01-D311-4EF3-9740-E8E80BF4F773
P2860
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Development of interpretive br ...... n Antifungal Susceptibility Te
@en
type
label
Development of interpretive br ...... n Antifungal Susceptibility Te
@en
prefLabel
Development of interpretive br ...... n Antifungal Susceptibility Te
@en
P2093
P356
P1476
Development of interpretive br ...... n Antifungal Susceptibility Te
@en
P2093
Bartlett MS
Espinel-Ingroff A
Galgiani JN
Ghannoum MA
Lancaster M
Pfaller MA
Rinaldi MG
P304
P356
10.1093/CLINIDS/24.2.235
P407
P577
1997-02-01T00:00:00Z